Literature DB >> 22699977

Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.

B J Lee1, J H Kim, H Heo, Y S Yu.   

Abstract

PURPOSE: To report a series of patients who presented with an atypical retinal traction band, which was developed after an intravitreal injection of bevacizumab for stage 3 retinopathy of prematurity (ROP).
METHODS: We retrospectively reviewed the medical record of three patients (five eyes) who had been referred to a tertiary care centre for the management of fibrous retinal traction band, which occurred after a bevacizumab injection for stage 3 ROP with plus disease. Clinical features and courses of these eyes were described based on the medical record and RetCam fundus photography.
RESULTS: All three patients had taken an intravitreal injection of bevacizumab with or without concomitant laser photocoagulation as an initial treatment option for the active stage 3 ROP. With close follow-ups, regression of extraretinal fibrovascular proliferation and plus disease was noted invariably. After the regression of ROP, atypical fibrous traction membrane had arisen along the major vascular arcades with 2.5 to 4 months of latency, which progressed into tractional retinal detachment (TRD) in three out of five eyes.
CONCLUSION: In active stage 3 ROP, fibrous tractional membrane and subsequent TRD along the major vascular arcades were developed unpredictably after the regression of neovascular activity following bevacizumab injection as an initial treatment. Therefore, ROP patients who received bevacizumab treatment without previous retinal photocoagulation should be closely followed for more than 4 months after the treatments even if the disease seems to have regressed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699977      PMCID: PMC3396159          DOI: 10.1038/eye.2012.111

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  16 in total

1.  Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity.

Authors:  Sun Young Jang; Kyung Seek Choi; Sung Jin Lee
Journal:  J AAPOS       Date:  2010-10       Impact factor: 1.220

2.  Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.

Authors:  L C Zepeda-Romero; J A Liera-Garcia; J A Gutiérrez-Padilla; C I Valtierra-Santiago; C D Avila-Gómez; L J Cardenas-Lamas
Journal:  Eye (Lond)       Date:  2009-06-26       Impact factor: 3.775

3.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Authors:  Wei-Chi Wu; Po-Ting Yeh; San-Ni Chen; Chung-May Yang; Chi-Chun Lai; Hsi-Kung Kuo
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

4.  Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.

Authors:  Joo Yong Lee; Ju Byung Chae; Sung Jae Yang; Young Hee Yoon; June-Gone Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09       Impact factor: 3.117

5.  Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.

Authors:  Kevin K Suk; Audina M Berrocal; Timothy G Murray; Ryan Rich; James C Major; Ditte Hess; Rose A Johnson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2010-12-22       Impact factor: 1.402

6.  Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.

Authors:  K Lashkari; T Hirose; J Yazdany; J W McMeel; A Kazlauskas; N Rahimi
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

7.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

8.  Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.

Authors:  Tatsuhiko Sato; Shunji Kusaka; Hiroshi Shimojo; Takashi Fujikado
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

9.  Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.

Authors:  S Kusaka; C Shima; K Wada; H Arahori; H Shimojyo; T Sato; T Fujikado
Journal:  Br J Ophthalmol       Date:  2008-07-11       Impact factor: 4.638

10.  Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.

Authors:  Geeta A Lalwani; Audina M Berrocal; Timothy G Murray; Maria Buch; Scott Cardone; Ditte Hess; Rose A Johnson; Carmen A Puliafito
Journal:  Retina       Date:  2008-03       Impact factor: 4.256

View more
  18 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  Intravitreal injection of bevacizumab for retinopathy of prematurity.

Authors:  Kazuki Kuniyoshi; Koji Sugioka; Hiroyuki Sakuramoto; Shunji Kusaka; Norihisa Wada; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2014-02-26       Impact factor: 2.447

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

Review 4.  Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?

Authors:  Andreas Stahl; Ann Hellstrom; Lois E H Smith
Journal:  Neonatology       Date:  2014-10-05       Impact factor: 4.035

Review 5.  Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Authors:  Nita G Valikodath; Michael F Chiang; R V Paul Chan
Journal:  Curr Opin Ophthalmol       Date:  2021-09-01       Impact factor: 4.299

6.  Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.

Authors:  Wendy Chen; Gil Binenbaum; Karen Karp; Agnieshka Baumritter; Denise J Pearson; Albert M Maguire; Graham E Quinn
Journal:  J AAPOS       Date:  2014-08-01       Impact factor: 1.220

Review 7.  Screening and Treatment in Retinopathy of Prematurity.

Authors:  Andreas Stahl; Wolfgang Göpel
Journal:  Dtsch Arztebl Int       Date:  2015-10-23       Impact factor: 5.594

Review 8.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

Review 9.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

10.  Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice.

Authors:  Dong Hyun Jo; Sung Wook Park; Chang Sik Cho; Michael B Powner; Jin Hyoung Kim; Marcus Fruttiger; Jeong Hun Kim
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.